The AVENIO Tumour Tissue Comprehensive Genomic Profiling (CGP) Kit
was developed with Roche unit Foundation Medicine, a molecular
information specialist whose products help doctors match patients to
appropriate therapies and clinical trials.
"The Kit complements the current CGP portfolio offered by Roche and
Foundation Medicine and allows laboratories to expand their oncology
research in-house," Roche said in a statement, giving no financial
information about the product.
[to top of second column] |
"Ultimately, a future version
of the kit may lead to additional resources for
clinicians to use in the diagnosis and treatment
of cancer."
(Reporting by Michael Shields)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |